Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Zerion Pharma Aps is navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct art units and distinct examiners. This distribution between actions, examiners, and art units suggests a diverse range of technical and administrative review for the portfolio.
PARK, HAEJIN S is the busiest examiner for the company, overseeing 1 pending office action. This accounts for a portion of the 2 total pending actions. The involvement of distinct examiners across 2 distinct art units indicates that the pending matters are being handled independently within the USPTO. For practitioners, this distribution means that the outcome of one pending action is unlikely to be influenced by the examiner or art unit handling the other.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.0% | +38.4% |
| SASAN, ARADHANA | 1 | 64.5% | +26.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564552 | CO-AMORPHOUS FORMS FOR USE IN CANCER THERAPY | SASAN, ARADHANA | 113d overdue |
| 18713118 | TERNARY CO-AMORPHOUS FORMS OF DRUGS, PROTEINS, AND WATER-SOLUBLE POLYMERS | PARK, HAEJIN S | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713118 | TERNARY CO-AMORPHOUS FORMS OF DRUGS, PROTEINS, AND WATER-SOLUBLE POLYMERS | PARK, HAEJIN S | 1614 | §102§103§112DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18564552 | CO-AMORPHOUS FORMS FOR USE IN CANCER THERAPY | SASAN, ARADHANA | 1615 | §103§112DP | Final Rejection | 113d overdue | Pending | Nov 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial